The Readout Loud
Ein Podcast von STAT - Donnerstags
350 Folgen
-
287: 2023 in review, CEO report cards, and a look at the year ahead
Vom: 21.12.2023 -
286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future
Vom: 14.12.2023 -
285: CRISPR history, biotech struggles, & a big week for deals
Vom: 7.12.2023 -
284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Vom: 30.11.2023 -
283: A CRISPR milestone, algorithms amok, & biotech mixology
Vom: 16.11.2023 -
From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?
Vom: 13.11.2023 -
282: Lilly’s obesity drug, the power of radiation, & a biotech implosion
Vom: 9.11.2023 -
281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
Vom: 2.11.2023 -
280: ESMO highlights, Roivant's big deal, & biotech VC on the rise
Vom: 26.10.2023 -
279: Live from the 2023 STAT Summit
Vom: 19.10.2023 -
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
Vom: 12.10.2023 -
277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus
Vom: 5.10.2023 -
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
Vom: 28.9.2023 -
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
Vom: 21.9.2023 -
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Vom: 14.9.2023 -
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Vom: 7.9.2023 -
272: Vivek's star turn, leaky drug data, & biotech as family business
Vom: 24.8.2023 -
271: Racing for gene therapy, a pioneering approval, & startups in the lurch
Vom: 18.8.2023 -
270: Your guide to Wegovy’s blockbuster heart study
Vom: 10.8.2023 -
269: Biotech layoffs, eye drug drama, & gene therapy milestones
Vom: 3.8.2023
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.